drugset

drugset / Trial / NCT00095927

Randomized Amifostine For SCCHN

NCT00095927 ↗

Phase 2 Completed 58 enrolled Dana-Farber Cancer Institute AstraZeneca · collab MedImmune LLC · collab National Cancer Institute (NCI) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.

Timeline

Start: 2003-05
Primary completion: 2007-06
Completion: 2008-06

Publications

Results Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 1;115(19):4514-23. doi: 10.1002/cncr.24525.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	amifostine	Unknown	500 mg	Subcutaneous
Background	Carboplatin	Small molecule	1.5 unknown	Intravenous
Background	Paclitaxel	Small molecule	45 mg/m2	Intravenous

Indications